Pharmaceutical companies are making such a significant financial commitment to product development and subsequent bioequivalence research. Since the FDA, EMA, and WHO terminated or issued warnings on numerous bioequivalence studies and CROs due to data integrity issues, pharmaceutical companies are now concerned about data integrity issues. For pharmaceutical businesses, not filing the product or waiting too long for clearance from various regulatory agencies results in substantial losses.
BEMONIT provides consulting and monitoring services for bioequivalence. During the pre-study, study and post-study periods, it can assist you in guaranteeing quality and regulatory compliance at CRO's, which helps to reduce risks by ensuring compliance at CROs.
BEMONIT Services at very low costs, which encourages pharmaceutical companies to think about outsourcing monitoring services, as advised by all international pharmaceutical regulatory authorities.